Due to the important role that arginine methylation plays in the development of cancer, PRMT5 has become a potential target for cancer treatment.

Hemab Therapeutics has reported the initial dosing of a participant in a Stage 2 medical trial assessing the efficacy of HMB-001 in addressing Glanzmann's Thrombasthenia.

The exact number of protein sequence variants caused by post-translational modifications (PTMs), which alter proteins after synthesis, is unclear.

NAYA Biosciences Reveals New Findings on Its CD38-Directed Flex-NK™ Dual-Specific Antibody in the Journal Published by the American Society of Hematology.

Ras inhibitors are drugs that target Ras proteins, crucial in cell signaling pathways. The future sees potential applications in treating various cancers.

IASO Bio alongside Innovent unveiled fresh Equecabtagene Autoleucel (FUCASO®) findings for those affected by multiple myeloma, during the 2023 ASH conference.

Adverse drug reaction (ADR) refers to the harmful reactions of qualified drugs that are unrelated to the purpose of medication under normal usage and dosage.

Qilu Pharma Releases Initial Clinical Data on New Dual-Target Antibody QLS31905 During ESMO Immuno-Oncology Meeting.

Proteasome inhibitors are a type of medication that interfere with the activity of proteasomes.

Electra Therapeutics unveils initial study results from their active Phase 1b trial of ELA026 designed to combat secondary HLH (hemophagocytic lymphohistiocytosis)

When patients take atropine to treat gastrointestinal pain, it is easy to produce side effects of blurred vision.

Agenus Inc., an innovator in immune-modulatory cancer treatments, announced reaching its second milestone in the global licensing agreement with Bristol Myers Squibb for BMS-986442, a bispecific TIGIT antibody with improved Fc functionality.